-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the China Hospital Drug Statistics Report released by Aikunwei, in the fourth quarter of 2021, the total sales of China's hospital drug market (sales of hospitals with more than 100 beds, calculated at the hospital purchase price) reached 223 billion yuan, a year-on-year increase of 2.
2%
.
Based on 12-month MAT (rolling full-year data) sales, the total sales of MAT in the fourth quarter of 2021 will be approximately 910.
3 billion yuan, a year-on-year increase of 9.
2%
.
2%
.
Based on 12-month MAT (rolling full-year data) sales, the total sales of MAT in the fourth quarter of 2021 will be approximately 910.
3 billion yuan, a year-on-year increase of 9.
2%
.
Market performance of multinational and local companies
From the perspective of different types of enterprises, in the fourth quarter of 2021, the sales of multinational enterprises were about 61.
6 billion yuan, a year-on-year decrease of 0.
9%; the sales of local enterprises were about 161.
4 billion yuan, a year-on-year increase of 3.
5%
.
In terms of quarterly sales and MAT annual sales, AstraZeneca, Yangzijiang Pharmaceuticals, and Hengrui Pharmaceuticals rank among the top three companies
.
The annual sales of MAT of multinational companies is nearly 258.
3 billion yuan, with a growth rate of 6.
3%; the annual sales of MAT of local companies is nearly 652.
1 billion yuan, with a growth rate of 10.
4% (see Table 1 for details)
.
6 billion yuan, a year-on-year decrease of 0.
9%; the sales of local enterprises were about 161.
4 billion yuan, a year-on-year increase of 3.
5%
.
In terms of quarterly sales and MAT annual sales, AstraZeneca, Yangzijiang Pharmaceuticals, and Hengrui Pharmaceuticals rank among the top three companies
.
The annual sales of MAT of multinational companies is nearly 258.
3 billion yuan, with a growth rate of 6.
3%; the annual sales of MAT of local companies is nearly 652.
1 billion yuan, with a growth rate of 10.
4% (see Table 1 for details)
.
Market performance of key therapeutic areas and key products
Throughout the major therapeutic areas, in the fourth quarter of 2021, the proportion of proprietary Chinese medicines in the hospital market is still ranked first, with quarterly sales of about 37.
5 billion yuan, a year-on-year increase of 6.
3%; MAT annual sales of about 145.
2 billion yuan , a year-on-year increase of 12.
6%
.
Anti- tumor and immunomodulatory agents ranked second, with quarterly sales of about 31.
5 billion yuan, a year-on-year increase of 5.
2%; MAT annual sales of nearly 129.
7 billion yuan, a year-on-year increase of 12.
7%, the growth rate ranked first in all categories (see details for details).
Table 2)
.
5 billion yuan, a year-on-year increase of 6.
3%; MAT annual sales of about 145.
2 billion yuan , a year-on-year increase of 12.
6%
.
Anti- tumor and immunomodulatory agents ranked second, with quarterly sales of about 31.
5 billion yuan, a year-on-year increase of 5.
2%; MAT annual sales of nearly 129.
7 billion yuan, a year-on-year increase of 12.
7%, the growth rate ranked first in all categories (see details for details).
Table 2)
.
Judging from the quarterly sales of products, Jiaronin of Yangzijiang Pharmaceutical continued to rank first, Supershen of Pfizer Group and NBP of CSPC ranked second and third respectively
.
Among the top ten products, 6 are from local companies and 4 are from multinational companies
.
Among them, the first domestic bevacizumab approved for marketing, Qilu Pharma’s Ankeda, has maintained a strong growth trend since its launch.
The sales in the latest quarter increased by 73.
2% year-on-year, and MAT’s year-on-year growth rate was as high as 181.
1%
.
Benefiting from the launch of the injectable dosage form and its inclusion in the national medical insurance, Livzon Group's Livzon Pharmaceutical's Elian also performed well, ranking second in the quarter-on-quarter growth rate of 40.
8%, and the MAT year-on-year growth rate reached 82.
7% (see the table for details).
3)
.
.
Among the top ten products, 6 are from local companies and 4 are from multinational companies
.
Among them, the first domestic bevacizumab approved for marketing, Qilu Pharma’s Ankeda, has maintained a strong growth trend since its launch.
The sales in the latest quarter increased by 73.
2% year-on-year, and MAT’s year-on-year growth rate was as high as 181.
1%
.
Benefiting from the launch of the injectable dosage form and its inclusion in the national medical insurance, Livzon Group's Livzon Pharmaceutical's Elian also performed well, ranking second in the quarter-on-quarter growth rate of 40.
8%, and the MAT year-on-year growth rate reached 82.
7% (see the table for details).
3)
.
(Data source: Statistical Report on Drugs of Chinese Hospitals by Ai Kunwei; Contributed by Ai Kunwei)
According to the China Hospital Drug Statistics Report released by Aikunwei, in the fourth quarter of 2021, the total sales of China's hospital drug market (sales of hospitals with more than 100 beds, calculated at the hospital purchase price) reached 223 billion yuan, a year-on-year increase of 2.
2%
.
Based on 12-month MAT (rolling full-year data) sales, the total sales of MAT in the fourth quarter of 2021 will be approximately 910.
3 billion yuan, a year-on-year increase of 9.
2%
.
2%
.
Based on 12-month MAT (rolling full-year data) sales, the total sales of MAT in the fourth quarter of 2021 will be approximately 910.
3 billion yuan, a year-on-year increase of 9.
2%
.
Market performance of multinational and local companies
From the perspective of different types of enterprises, in the fourth quarter of 2021, the sales of multinational enterprises were about 61.
6 billion yuan, a year-on-year decrease of 0.
9%; the sales of local enterprises were about 161.
4 billion yuan, a year-on-year increase of 3.
5%
.
In terms of quarterly sales and MAT annual sales, AstraZeneca, Yangzijiang Pharmaceuticals, and Hengrui Pharmaceuticals rank among the top three companies
.
The annual sales of MAT of multinational companies is nearly 258.
3 billion yuan, with a growth rate of 6.
3%; the annual sales of MAT of local companies is nearly 652.
1 billion yuan, with a growth rate of 10.
4% (see Table 1 for details)
.
6 billion yuan, a year-on-year decrease of 0.
9%; the sales of local enterprises were about 161.
4 billion yuan, a year-on-year increase of 3.
5%
.
In terms of quarterly sales and MAT annual sales, AstraZeneca, Yangzijiang Pharmaceuticals, and Hengrui Pharmaceuticals rank among the top three companies
.
The annual sales of MAT of multinational companies is nearly 258.
3 billion yuan, with a growth rate of 6.
3%; the annual sales of MAT of local companies is nearly 652.
1 billion yuan, with a growth rate of 10.
4% (see Table 1 for details)
.
Market performance of key therapeutic areas and key products
Throughout the major therapeutic areas, in the fourth quarter of 2021, the proportion of proprietary Chinese medicines in the hospital market is still ranked first, with quarterly sales of about 37.
5 billion yuan, a year-on-year increase of 6.
3%; MAT annual sales of about 145.
2 billion yuan , a year-on-year increase of 12.
6%
.
Anti- tumor and immunomodulatory agents ranked second, with quarterly sales of about 31.
5 billion yuan, a year-on-year increase of 5.
2%; MAT annual sales of nearly 129.
7 billion yuan, a year-on-year increase of 12.
7%, the growth rate ranked first in all categories (see details for details).
Table 2)
.
5 billion yuan, a year-on-year increase of 6.
3%; MAT annual sales of about 145.
2 billion yuan , a year-on-year increase of 12.
6%
.
Anti- tumor and immunomodulatory agents ranked second, with quarterly sales of about 31.
5 billion yuan, a year-on-year increase of 5.
2%; MAT annual sales of nearly 129.
7 billion yuan, a year-on-year increase of 12.
7%, the growth rate ranked first in all categories (see details for details).
Table 2)
.
Judging from the quarterly sales of products, Jiaronin of Yangzijiang Pharmaceutical continued to rank first, Supershen of Pfizer Group and NBP of CSPC ranked second and third respectively
.
Among the top ten products, 6 are from local companies and 4 are from multinational companies
.
Among them, the first domestic bevacizumab approved for marketing, Qilu Pharma’s Ankeda, has maintained a strong growth trend since its launch.
The sales in the latest quarter increased by 73.
2% year-on-year, and MAT’s year-on-year growth rate was as high as 181.
1%
.
Benefiting from the launch of the injectable dosage form and its inclusion in the national medical insurance, Livzon Group's Livzon Pharmaceutical's Elian also performed well, ranking second in the quarter-on-quarter growth rate of 40.
8%, and the MAT year-on-year growth rate reached 82.
7% (see the table for details).
3)
.
.
Among the top ten products, 6 are from local companies and 4 are from multinational companies
.
Among them, the first domestic bevacizumab approved for marketing, Qilu Pharma’s Ankeda, has maintained a strong growth trend since its launch.
The sales in the latest quarter increased by 73.
2% year-on-year, and MAT’s year-on-year growth rate was as high as 181.
1%
.
Benefiting from the launch of the injectable dosage form and its inclusion in the national medical insurance, Livzon Group's Livzon Pharmaceutical's Elian also performed well, ranking second in the quarter-on-quarter growth rate of 40.
8%, and the MAT year-on-year growth rate reached 82.
7% (see the table for details).
3)
.
(Data source: Statistical Report on Drugs of Chinese Hospitals by Ai Kunwei; Contributed by Ai Kunwei)
According to the China Hospital Drug Statistics Report released by Aikunwei, in the fourth quarter of 2021, the total sales of China's hospital drug market (sales of hospitals with more than 100 beds, calculated at the hospital purchase price) reached 223 billion yuan, a year-on-year increase of 2.
2%
.
Based on 12-month MAT (rolling full-year data) sales, the total sales of MAT in the fourth quarter of 2021 will be approximately 910.
3 billion yuan, a year-on-year increase of 9.
2%
.
2%
.
Based on 12-month MAT (rolling full-year data) sales, the total sales of MAT in the fourth quarter of 2021 will be approximately 910.
3 billion yuan, a year-on-year increase of 9.
2%
.
Market performance of multinational and local companies
Market performance of multinational and local companies From the perspective of different types of enterprises, in the fourth quarter of 2021, the sales of multinational enterprises were about 61.
6 billion yuan, a year-on-year decrease of 0.
9%; the sales of local enterprises were about 161.
4 billion yuan, a year-on-year increase of 3.
5%
.
In terms of quarterly sales and MAT annual sales, AstraZeneca, Yangzijiang Pharmaceuticals, and Hengrui Pharmaceuticals rank among the top three companies
.
The annual sales of MAT of multinational companies is nearly 258.
3 billion yuan, with a growth rate of 6.
3%; the annual sales of MAT of local companies is nearly 652.
1 billion yuan, with a growth rate of 10.
4% (see Table 1 for details)
.
Pharmaceutical pharmaceutical pharmaceutical enterprise enterprise enterprise6 billion yuan, a year-on-year decrease of 0.
9%; the sales of local enterprises were about 161.
4 billion yuan, a year-on-year increase of 3.
5%
.
In terms of quarterly sales and MAT annual sales, AstraZeneca, Yangzijiang Pharmaceuticals, and Hengrui Pharmaceuticals rank among the top three companies
.
The annual sales of MAT of multinational companies is nearly 258.
3 billion yuan, with a growth rate of 6.
3%; the annual sales of MAT of local companies is nearly 652.
1 billion yuan, with a growth rate of 10.
4% (see Table 1 for details)
.
Market performance of key therapeutic areas and key products
Market performance of key therapeutic areas and key products Throughout the major therapeutic areas, in the fourth quarter of 2021, the proportion of proprietary Chinese medicines in the hospital market is still ranked first, with quarterly sales of about 37.
5 billion yuan, a year-on-year increase of 6.
3%; MAT annual sales of about 145.
2 billion yuan , a year-on-year increase of 12.
6%
.
Anti- tumor and immunomodulatory agents ranked second, with quarterly sales of about 31.
5 billion yuan, a year-on-year increase of 5.
2%; MAT annual sales of nearly 129.
7 billion yuan, a year-on-year increase of 12.
7%, the growth rate ranked first in all categories (see details for details).
Table 2)
.
hospital hospital hospital tumor tumor tumor5 billion yuan, a year-on-year increase of 6.
3%; MAT annual sales of about 145.
2 billion yuan , a year-on-year increase of 12.
6%
.
Anti- tumor and immunomodulatory agents ranked second, with quarterly sales of about 31.
5 billion yuan, a year-on-year increase of 5.
2%; MAT annual sales of nearly 129.
7 billion yuan, a year-on-year increase of 12.
7%, the growth rate ranked first in all categories (see details for details).
Table 2)
.
Judging from the quarterly sales of products, Jiaronin of Yangzijiang Pharmaceutical continued to rank first, Supershen of Pfizer Group and NBP of CSPC ranked second and third respectively
.
Among the top ten products, 6 are from local companies and 4 are from multinational companies
.
Among them, the first domestic bevacizumab approved for marketing, Qilu Pharma’s Ankeda, has maintained a strong growth trend since its launch.
The sales in the latest quarter increased by 73.
2% year-on-year, and MAT’s year-on-year growth rate was as high as 181.
1%
.
Benefiting from the launch of the injectable dosage form and its inclusion in the national medical insurance, Livzon Group's Livzon Pharmaceutical's Elian also performed well, ranking second in the quarter-on-quarter growth rate of 40.
8%, and the MAT year-on-year growth rate reached 82.
7% (see the table for details).
3)
.
.
Among the top ten products, 6 are from local companies and 4 are from multinational companies
.
Among them, the first domestic bevacizumab approved for marketing, Qilu Pharma’s Ankeda, has maintained a strong growth trend since its launch.
The sales in the latest quarter increased by 73.
2% year-on-year, and MAT’s year-on-year growth rate was as high as 181.
1%
.
Benefiting from the launch of the injectable dosage form and its inclusion in the national medical insurance, Livzon Group's Livzon Pharmaceutical's Elian also performed well, ranking second in the quarter-on-quarter growth rate of 40.
8%, and the MAT year-on-year growth rate reached 82.
7% (see the table for details).
3)
.
(Data source: Statistical Report on Drugs of Chinese Hospitals by Ai Kunwei; Contributed by Ai Kunwei)
medicines medicines medicines 
